References
- Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012;12(1):44–51.
- Blau EB. Familial granulomatous arthritis, isitis, and rash. J Pediatr. 1985;107(5):689–693.
- Jabs DA, Houk JL, Bias WB, et al. Familial granulomatous synovitis, uveitis and cranial neuropathies. Am J Med. 1985;78(5):801–804.
- Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical and therapeutic issues. Int J Rheumatol. 2013;2013:1.
- Punzi L, Furlan A, Podswiadek M, et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev. 2009;8(3):228–232.
- Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105(3):1195–1197.
- Rybicki BA, Maliarik MJ, Bock CH, et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):203–208.
- Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014;13(12):1220–1229.
- Sarens IL, Casteels I, Anton J, et al. Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am J Ophthalmol. 2018;187:158–166.
- Kurokawa T, Kikuchi T, Ohta K, et al. Ocular manifestation in Blau syndrome associated with a CARD15/NOD2 mutation. Ophtalmology. 2003;110(10):2040–2044.
- Ohmen JD, Yang HY, Yamamoto KK, et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Chron’s disease, but not in ulcerative colitis. Hum Mol Genet. 1996;5(10):1679–1683.
- Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29(1):19–20.
- Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–8872.
- Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet. 1996;59(5):1097–1107.
- Yao Q. Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases. Semin Arthritis Rheu. 2013;43(1):125–130.
- Chamaillard M, Philpott D, Girardin SE, et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory disease. Proc Natl Acad Sci USA. 2003;100(6):3455–3460.
- Rosenbaum JT, Planck SR, Davey MP, et al. With a mere nod, uveitis enters a new era. Am J Ophthalmol. 2003;136(4):729–732.
- Borzutzky A, Fried A, Chou J, et al. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin Immunol. 2010;134(3):251–261.
- Raiji VR, Miller MM, Jung LK. Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS. 2011;15(2):205–207.
- Zeybek C, Basbozkurt G, Gul D, et al. A new mutation in Blau Syndrome. Case Rep Rheumatol. 2015;2015:463959
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.
- Nykamp K, Anderson M, Powers M, et al. Sherlock: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med. 2017; 19(10):1105–1117.
- Tanabe T, Chamaillard M, Ogura Y, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 2004;23(7):1587–1597.
- Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–315.
- Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31(5):761–763.